StockNews.com assumed coverage on shares of Omeros (NASDAQ:OMER – Get Rating) in a research note issued to investors on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Separately, UBS Group lowered shares of Omeros from a buy rating to a neutral rating in a report on Thursday, December 8th.
Omeros Price Performance
Omeros stock opened at $3.54 on Thursday. The stock has a market cap of $222.42 million, a price-to-earnings ratio of 4.72 and a beta of 1.02. Omeros has a 12-month low of $1.74 and a 12-month high of $7.75. The company has a quick ratio of 7.30, a current ratio of 3.25 and a debt-to-equity ratio of 2.58. The business’s 50-day simple moving average is $3.61 and its 200 day simple moving average is $3.28.
Institutional Trading of Omeros
Omeros Company Profile
Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system.
- Get a free copy of the StockNews.com research report on Omeros (OMER)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.